SummaryIn the present analysis, we evaluate the standard of care in radiation therapy for benign diseases in Germany. The German Cooperative Group on Benign Diseases evaluated all German institutions via mailed questionnaires and analyzed data from 36,830 patients who were irradiated for benign disorders. The results demonstrate a wide acceptance of this treatment in Germany.Alt-text: Unlabelled box

Introduction {#s0010}
============

In contrast to Germany, where radiation therapy (RT) is commonly used and well accepted in the treatment of benign diseases, its use is rarely applied in other countries, Anglo-American regions in particular. Several publications show the low acceptance and worldwide undulation of RT for benign diseases.[@bib0010], [@bib0015]

Nevertheless, many German publications reflect the significance of RT across the country,[@bib0020], [@bib0025], [@bib0030] which is due primarily to the foundation of the German Cooperative Group on Benign Diseases (GCG-BD) in 1996 by the German Society for Radiation Oncology (DEGRO). This group was founded to train physicians in the treatment of benign diseases, coordinate scientific work and clinical trials, and improve experience within this entity.

The GCG-BD conducted many patterns-of-care studies (PCSs) to evaluate the standard of treatment.[@bib0035], [@bib0040], [@bib0045], [@bib0050] In 2015, DEGRO published guidelines for radiotherapeutic treatment of nonmalignant disorders.[@bib0055], [@bib0060], [@bib0065], [@bib0070] All of this underlines the value of RT for benign diseases in Germany, resulting from the work and annually organized scientific meetings of the GCG-BD. Seegenschmiedt et al conducted the first national PCS in 1994, 1995, and 1996 to evaluate technical equipment, treatment concepts, treatment indications, and numbers of patients.[@bib0040]

Although guidelines are available, treatment concepts are inconsistent. Therefore, we conducted this national PCS on behalf of the GCG-BD and DEGRO to evaluate the actual treatment standard in Germany and to compare the results with previous findings.

Methods and materials {#s0015}
=====================

In 2015, a questionnaire was mailed to all radiation therapy institutions in Germany, Austria, and Switzerland. After 8 weeks, the nonresponding centers were contacted via phone and mail. After another 8 weeks, the remaining centers were contacted again.

The questionnaire was used to collect the following information: 1) general information, 2) type and number of technical equipment, 3) number of patients, and 4) specific information. In a second part, data were collected to assess the following 5 subgroups of benign dysfunctions: a) degenerative, b) hyperproliferative, c) functional, d) stereotactic RT in the central nervous system (CNS), and e) rare indications. The values collected were the number of patients per disease category, single entity, single and total doses applied, fractions per week, total fractions, and number of treatment courses. The Kolmogorov-Smirnov, Shapiro-Wilk, and Kruskal-Wallis tests were applied using SPSS (version 24.0).

Results {#s0020}
=======

General information and technical equipment {#s0025}
-------------------------------------------

Of the 116 questionnaires that were returned by institutions (35%), 20 (17%) were from university hospitals, 27 (23%) from municipal hospitals, 28 (25%) from private institutions, and 41 (32%) from ambulatory health care centers ([Figure 1](#f0010){ref-type="fig"}). On average, 2 linac accelerators (range, 1-6) and 2 megavoltage units were available at each institution. Additionally, 27 institutions used orthovoltage units with a median age of 17 years (range, 1-52 years). In comparison, the linac accelerators had a median age of 5 years (range, 1-18 years).Figure 1Participating centers in Germany.Figure 1

Treatment indications and treatment concepts {#s0030}
--------------------------------------------

In total, of the 53,932 patients receiving RT in 2014, 36,830 (68%) had benign diseases. Of those, 16,989 patients (46%) were treated for degenerative diseases, another 14,936 (40%) for osteoarthritis, 1563 (4%) for hyperproliferative diseases, and 2440 (7%) for functional disorders. Of the remainder, 859 (2%) received stereotactic RT of the CNS, and 43 patients were irradiated because of rare indications.

Degenerative diseases included peritendinitis humeroscapularis (n = 2691), epicondylitis humeri (n = 3788), and heel spur (n = 10,510). Osteoarthritis included coxarthrosis (n = 2230), gonarthrosis (n = 2623), omarthrosis (n = 2691), rhizarthrosis (n = 2440), polyarthrosis (n = 2297), and others (n = 2655). Hyperproliferative diseases included morbus Dupuytren (n = 960), morbus Ledderhose (n = 441), keloids (n = 139), pterygium of the conjunctiva (n = 3), and other hyperproliferative diseases (n = 20). Functional disorders included gynecomastia (n = 843), Graves\' disease (n = 205), lymphatic fistula (n = 178), and heterotopic ossification prophylaxis (n = 1214). Stereotactic RT of the CNS included arteriovenous malformation (n = 53), meningioma (n = 425), acoustic neuroma (n = 201), pituitary adenoma (n = 131), and others (n = 49). Other rare indications were pigmented villonodular synovitis (n = 20) and vertebral hemangioma (n = 23).

Not all institutions revealed their treatment concepts in detail, but information from 80 institutions (68%) was available. The mean total dose was \<10 Gy (range, 0.45-8 Gy) in the treatment of degenerative disorders, 25 Gy for hyperproliferative diseases (range, 8.75-30 Gy), 15 Gy for functional disorders (range, 2.1-40 Gy), and \<50 Gy (range, 21-60 Gy) for stereotactic RT. Further details are shown in [Table 1](#t0010){ref-type="table"}, [Table 2](#t0015){ref-type="table"}.Table 1Detailed information of treatmentTable 1Disease categoryUniversity hospitalCommunity hospitalMedical practiceAmbulatory health care centerAll institutions**Degenerative diseases**Total institutionsn = 15n = 19n = 13n = 28n = 75Total patients4582 (13.5%)7692 (22.6%)6180 (18.1%)15,588 (45,8%)34,042 (100%)Patients (mean ± SD)11 ± 536250 ± 495350 ± 417245 ± 690258 ± 572Range11-21025-69237-15000-28180-2818**Hyperproliferative diseases**Total institutionsn = 15n = 17n = 12n = 24n = 68Total patients283 (22.5%)232 (18.4%)226 (18%)518 (41.1%)1259 (100%)Patients (mean ± SD)5 ± 498 ± 1417 ± 159 ± 428 ± 35Range0-1940-461-510-2060-206**Functional diseases**Total institutionsn = 16n = 20n = 14n = 22n = 72Total patients403 (16.9%)908 (38.1%)439 (18.4%)634 (26.6%)2384 (100%)Patients (mean ± SD)21 ± 2125 ± 6815 ± 6121 ± 2320 ± 47Range3-902-3142-2410-750-314**Stereotactic indications**Total institutionsn = 15n = 12n = 9n = 21n = 57Total patients654 (77.9%)50 (6%)21 (2.5%)114 (13.6%)839 (100%)Patients (mean ± SD)30 ± 612 ± 60 ± 60 ± 122 ± 36Range3-2490-170-170-370-249**Rare indications**Total institutionsn = 11n = 10n = 12n = 20n = 53Total patients20 (40.8%)4 (8.2%)15 (30.6%)10 (20.4%)49 (100%)Patients (mean ± SD)1 ± 30 ± 10 ± 30 ± 10 ± 2Range0-80-10-80-50-8[^1]Table 2Dosage and fractionationTable 2DiagnosisSingle dose (Gy)Total dose (Gy)Fraction schedule**Degenerative diseases**Painful joints: insertion tendinitis0.45-12-82-4x/weekPainful joints: arthritis0.5-12-81-4x/week**Hyperproliferative diseases**M. Dupuytren2-715-303-10x/weekM. Ledderhose0.5-73-202-5x/weekKeloid1-7.57-202-5x/weekPterygium5-108,75-201-2x/week**Functional diseases**Gynecomastia1.8-1210-251-5x/weekLymphatic fistula0.5-32,5-402-5x/weekEndocrine orbitopathia0.3-102,1-241-5x/weekHeterotopic ossification1-86-121-5x/week**Stereotactic indications**Ateriovenosis malformation1.8-22.512-541-5x/weekMenigioma1.8-1814-601-5x/weekAcoustic neuroma2-1514-601-5x/weekPituitary adenoma1.5-2513-541-5x/week

Of the 80 institutions that provided details about specializations, 36 (45%) provided specialized consultation hours for benign diseases. Of the 69 institutions that provided details about clinical studies, 19 (27.5%) participated in them. Of the 64 institutions that provided details about publishing results, 10 (15.6%) publish their own results.

Discussion {#s0035}
==========

This PCS shows the wide acceptance of RT for treatment of benign diseases across Germany. Benign indications account for more than one-third of all patients treated annually. The first PCS of RT for benign diseases was conducted by Seegenschmiedt et al in 1994 through 1996 and included 20,082 patients treated annually.[@bib0040] The number of patients has nearly doubled within 20 years. This could be due to a number of reasons. First, Germany now has 340 active centers, compared with 152 in 1996. Because several studies have demonstrated the effectiveness of RT for benign diseases,[@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095], [@bib0100] RT is commonly used for several benign indications. In comparison with the first PCS, there is no change within the treatment concepts but rather a change in indications. Only 155 patients in the first PCS were treated because of meningioma, acoustic neuroma, or pituitary adenoma in contrast with the 757 patients in the present PCS.

There are retrospective data that encourage RT for degenerative diseases,[@bib0035], [@bib0040], [@bib0105], [@bib0110] but unfortunately there are no prospective trials comparing RT with surgical treatment or the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in this setting. One of the best-evaluated indications within randomized trials is the use of RT in heterotopic ossification prophylaxis.[@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095] A risk--benefit ratio is available, and the 2 treatment options are perioperative RT and NSAIDs. Gregoritch et al and Knelles et al reported improved outcomes in hip function in contrast with no treatment and generally better outcomes for both RT and NSAIDs. Although RT shows treatment-related advantages in toxicity and patient compliance, NSAIDs are not as expensive and are more easily accessible.[@bib0075], [@bib0080]

Another indication with possible long-term follow-up data is RT for morbus Dupuytren. Nonradiotherapeutic treatment options are vitamins or steroids and surgical approaches. The efficacy of RT depends on the stage of disease. Betz et al studied patients with a median follow-up of 13 years and found avoidance of progression and improvement in 87% of patients in a stage with only nodules and chords and in 70% of patients with extension deficits.[@bib0100]

Another possible reason for widespread use of RT for benign diseases in German-speaking countries is that several studies and PCS of benign disorders conducted by the GCG-BD show the state of treatment and the possible indications, although major prospective trials remain to be seen[@bib0035], [@bib0040], [@bib0050], [@bib0105], [@bib0110] to underline the effectiveness. Prospective randomized trials especially would further encourage the use of RT in benign diseases.

Because the performed PCS focused on special indications, this analysis calls into question the state of treatment in Germany. In comparison with the United States and other European countries, the use of RT for benign diseases is well accepted because of the available data, low side effects, and wide acceptance within the patient population. The contrast between eastern and western countries that was reported in the first PCS was not seen in the present analysis. There is also no difference between country and urban areas.

The participation of the centers varied between several PCS. Muecke et al obtained the best participation in their PCS on painful gonarthrosis:. Of 248 institutions, 238 (95.9%) completed their questionnaires.[@bib0035] Seggenschmiedt et al received participation from 134 of 152 institutions (88%).[@bib0040] Fewer questionnaires were completed for the study conducted by Micke et al in a PCS on painful heel spurs (101 returns) and on desmoid tumors (146 returns).[@bib0050], [@bib0110] In comparison, we received 116 completed questionnaires, which is comparable to the number of questionnaires used in the first general PCS by Seegenschmiedt et al.[@bib0040]

Perhaps because of the wide distribution of centers, only a few chose to participate in the PCS questionnaires. In the past years, many private and therefore cost-oriented institutions were established, and their interest in research participation may be low. Only 19 institutions (5.5%) were interested in clinical studies and participated in studies, and only 10 institutions (2.9%) published their data. This is comparable to prior findings. In 1996, only 4% of participating centers participated in clinical studies.[@bib0040]

The high rate of patients (68%) who were treated for benign diseases among the patient populations we evaluated must be interpreted with care. On one hand, we received only 116 completed questionnaires, so there is a bias in the data. On the other hand, this could be a realistic number because 25% were private institutions and 32% were ambulatory health care centers that treat large numbers of patients with benign diseases.

Within the past few years, technical equipment has changed substantially. In 1996, 104 cobalt units were available, and 102 institutions had orthovoltage devices. We found no institutions treating with cobalt units, and only 27 centers used orthovoltage units. This reflects the high standard of treatment across Germany and possibly accounts for the wide acceptance of RT. Long-term toxicity and radiation-induced malignancies are feared and associated with old-fashioned equipment and the use of orthovoltage units. Another change due to the technological improvement in the past years is the increased number of patients treated for meningioma, acoustic neuroma, and pituitary adenoma.

Recently, because of the large amount of data available from clinical studies, PCS guidelines have been published by the GCG-BD on behalf of the DEGRO. They serve as a model in the treatment of benign diseases. In particular, when facing rare indications, treating physicians are encouraged to follow these guidelines. In addition, existing guidelines will encourage even more acceptance of RT in the treatment of benign diseases. Nevertheless, due to the heterogeneity of RT concepts, clinical studies should be encouraged to optimize treatment strategies and promote the responsible use of RT for patients with benign diseases.

Conclusions {#s0040}
===========

This analysis underscores the widespread use of RT in the treatment of benign disorders in Germany. The large number of treated patients demonstrates the wide acceptance of this treatment option. Several published clinical studies, PCSs, and, in the last several years, consensus guidelines have helped establish this treatment. For benign diseases, RT continues to play an important treatment role.
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